OncoMatch/Clinical Trials/NCT07246304
TC-D101 Cell Therapy for Patients With DLL3-Positive SCLC
Is NCT07246304 recruiting? Yes, currently enrolling (Jun 2026). This Early Phase 1 trial studies TC-D101 CAR-T for small cell lung cancer ( sclc ).
Treatment: TC-D101 CAR-T — This is a single-arm, open-label, dose-escalation clinical trial designed to evaluate the safety, tolerability, expansion, and persistence of TC-D101 CAR-T cells in patients with DLL3-positive Relapsed/Refractory primary small cell lung cancer(r/r SCLC) who have progressed after prior therapies. The primary objective is to determine the maximum tolerated dose (MTD), with a secondary aim to assess preliminary clinical efficacy in SCLC.
Check if I qualifyExtracted eligibility criteria
Treatments studied
Other
Cancer type
Small Cell Lung Cancer
Biomarker criteria
Required: DLL3 positive by immunohistochemistry
DLL3-positive r/r SCLC confirmed by immunohistochemistry
Performance status
ECOG 0–1(Restricted strenuous activity)
Demographics
Prior therapy
Must have received: standard therapy
Failed or unsuitable for standard therapy
Cannot have received: cell or gene therapy
Prior cell or gene therapy
Lab requirements
Blood counts
Adequate bone marrow function
Kidney function
Liver function
Adequate organ and bone marrow function
Structured fields extracted by AI. May contain errors — verify against the official protocol.
Frequently asked questions
Is NCT07246304 currently recruiting?
Yes, this trial is currently recruiting patients.
Are there prior therapy exclusions?
Yes. Prior cell or gene therapy disqualifies patients from enrollment.
Does this trial require DLL3?
Yes, DLL3 positive by immunohistochemistry is a required biomarker for enrollment.
Is there an age limit?
Yes. Patients must be 75 years or younger.
Could you qualify for this trial?
Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.
Check if I qualifyRelated pages